Particle Dynamics

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Torrent Pharmaceuticals will purchase roughly a 46% stake in JB Chemicals in a deal worth 11.9 billion rupees ($1.38 billion), and then the two companies will enter a merger agreement, according to a Sunday release. The deal gives Ahmedabad-based Torrent access to JB’s “fast-growing” India franchise and CDMO capabilities. It should also expand Torrent’s international footprint. JB has a big presence in India’s hypertension market but also has significant market share in Russia and South Africa. It exports its drugs to more than 40 countries including the US. Contract manufacturer Future Pak will acquire Theratechnologies in a deal worth up to $254 million, according to a Wednesday release. The move will be made via Future Pak’s affiliate, CB Biotechnology. This is Future Pak’s first addition of a pharma group into its portfolio. Theratechnologies has faced some supply issues for its HIV drug, Egrifta SV, in recent months over issues at a third-party manufacturer. Sandoz has started construction of a $440 million biosimilar production facility in Brnik, Slovenia, the company said Tuesday. Piramal Pharma Solutions is spending $90 million to expand its drug substance and API site in Riverview, MI, and its fill-finish factory in Lexington, KY. The Riverview expansion is expected to be completed by the end of the year and the Lexington factory by late 2027, according to the Monday release. Simtra BioPharma Solutions has finished its expansion of its sterile injectable factory in Halle, Germany, according to a Monday release. The expansion added 150 new jobs. EuroAPI is selling its UK site in Haverhill to Particle Dynamics, the company said Monday. No financial details were disclosed. Particle will take on the projects at the Haverhill site, where 80% of revenue is attributed to Sanofi. EuroAPI spun out of Sanofi in April 2022. Soligenix has transferred manufacturing of its synthetic hypericin API to Sterling Pharma Solutions. Sterling will make this API for Soligenix for its clinical trials, with the goal of potentially also making this commercially down the line. The APIs are used in topical drugs to treat skin lesions. Klotho Neurosciences has started making clinical trial materials for its amyotrophic lateral sclerosis (ALS) gene therapy candidate, codenamed KLTO-202, the company said Monday. Cell and gene therapy CDMO ProBio has opened its Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, NJ. The new 128,000-square-foot site will make DNA plasmids and viral vectors, according to a Friday release. CDMO Vetter has started construction of its new $285 million clinical manufacturing facility in Des Plaines, IL, according to a Friday release. EQT Healthcare Growth is to acquire a majority stake in chemical and reagent supplier Europa Biosite, the company said Thursday. No financial details were disclosed. Neurizon Therapeutics has signed a licensing agreement with Elanco Animal Health for its API called Monepantel. The API is used in the development of its lead asset which is being investigated as a treatment for ALS. Axplora is spending €35 million to expand a facility in Italy, the company said Monday. With additional reporting by Ayisha Sharma and Reynald Castaneda.

Particle Dynamics Acquires EuroAPI UK to Expand Global Spray Drying Capabilities Strategic acquisition adds a commercial-scale, GMP-compliant site with two decades of expertise in Haverhill, UK The acquisition strengthens Particle Dynamics' global particle engineering capabilities and expands the market segments it serves The Haverhill team has longstanding experience and expertise, having delivered commercial-scale spray drying for over two decades. ST. LOUIS, June 30, 2025 /PRNewswire/ -- Particle Dynamics, a global leader in particle processing and delivery technologies, has acquired EUROAPI UK Ltd., an operator of a commercial spray drying facility in Haverhill, UK. The acquisition strengthens Particle Dynamics' position as a global CDMO and adds significant spray drying expertise and capacity. The Haverhill facility brings more than 20 years of spray drying experience, a mature quality management system, and a strong GMP track record. Particle Dynamics plans to invest in additional capabilities and talent, positioning the site to serve both clinical and commercial-scale projects. Nicolas Fortin, CEO of Particle Dynamics said, "The Haverhill site is a hidden gem; an exceptionally well-maintained facility with an experienced team in place, already delivering commercial-scale spray drying for more than two decades. In addition, the site has an impeccable quality track record. I'm delighted that through this acquisition, Particle Dynamics will extend its clinical and commercial offering to help meet the industry's growing demand for improved bioavailability, solubility and stability of therapeutic compounds." He continued, "I'm pleased to welcome Nicholas Hodgson and the Haverhill team to Particle Dynamics. This site will be a blueprint for operational excellence in our global network." About Particle Dynamics Particle Dynamics is a global leader in particle processing, delivery technologies and finished dose manufacturing for the nutraceutical, consumer health, OTC, and pharmaceutical sectors. The company provides a wide range of products and services, including formulation development, commercial manufacturing, API development, and packaging. Particle Dynamics has a proven track record of delivering high-quality GMP products and services that meet the needs of its customers. The company is committed to providing its customers with the highest level of customer service. Visit us at For Further Information Contact: Connor Halverson Tel: +1 212 366 4455 Email: [email protected] SOURCE Particle Dynamics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED